Table 1.
Clinical characteristics of the 55 patients with multiple myeloma.
| Characteristics | Number (%) or median (range) |
|---|---|
| Number of patients | 55 |
| Age | 61 (38–78) |
| Gender (male : female) | 36 : 19 (65 : 35) |
| Durie-Salmon stage (I : II : III) | 5 : 10 : 40 (9 : 18 : 73) |
| ISS stage (I : II : III) | 22 : 18 : 15 (40 : 33 : 27) |
| Calcium (mg/dL) | 9.1 (7.2–13.0) |
| Creatinine (mg/dL) | 1.2 (0.7–3.9) |
| Albumin (mg/dL) | 4.0 (2.3–4.9) |
| β2-Microglobulin (mg/dL) | 3.8 (1.6–19.0) |
| Hemoglobin (g/dL) | 10.3 (6.0–16.2) |
| Lactate dehydrogenase (U/L) | 167 (79–1832) |
| C-reactive protein (mg/dL) | 0.27 (0–10.01) |
| IgG : IgA : IgM : IgD : IgE : light* : biclonal | 33 : 11 : 0 : 0 : 0 : 9 : 2 (60 : 20 : 0 : 0 : 0 : 16 : 4) |
| Kappa : Lambda (electrophoresis) | 23 : 22† (51 : 49) |
| Plasma cell type | |
| Mature | 39 (71) |
| Immature | 9 (16) |
| Plasmablastic | 2 (4) |
| Pleomorphic | 5 (9) |
| Infiltration pattern | |
| Interstitial | 16 (29) |
| Focal | 3 (5) |
| Diffuse | 36 (66) |
| Frequency of CD138-positive cells on biopsy‡ | 80 (10–100) |
| Cytogenetics (FISH) | |
| 1q gain† | 21/47 (45) |
| 13q deletion† | 19/47 (40) |
| t(4;14)† | 8/48 (17) |
| 17p deletion† | 2/41 (5) |
ISS: international staging system; FISH: fluorescent in situ hybridization; *light chain type; †absent values due to tests not done; the percentages are calculated based on the number of tests completed; ‡immunohistochemical stain on bone marrow biopsy.